We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+26.16%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$277M
AUM Growth
-$60.9M
Cap. Flow
-$112M
Cap. Flow %
-40.48%
Top 10 Hldgs %
46.86%
Holding
81
New
21
Increased
12
Reduced
18
Closed
29

Top Buys

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$16.6M
2
COR icon
Cencora
COR
+$7.84M
3
SNN icon
Smith & Nephew
SNN
+$7.09M
4
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$6.82M
5
ACH
Accendra Health
ACH
+$5.26M

Top Sells

Rank Stock Value
1
EHC icon
Encompass Health
EHC
+$15M
2
IART icon
Integra LifeSciences
IART
+$13.3M
3
AHCO icon
AdaptHealth
AHCO
+$11.4M
4
ABBV icon
AbbVie
ABBV
+$11M
5
BMY icon
Bristol-Myers Squibb
BMY
+$8.98M

Sector Composition

Rank Sector Weight
1 Healthcare 93.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FSTX
51
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$202K 0.07%
+20,445
New +$134K
ADCT icon
52
ADC Therapeutics
ADCT
$144M
– –
-12,000
Closed -$396K
ALC icon
53
Alcon
ALC
$35B
– –
-38,373
Closed -$2.19M
ARCT icon
54
Arcturus Therapeutics
ARCT
$211M
– –
-34,485
Closed -$1.48M
AXGN icon
55
Axogen
AXGN
$2.5B
– –
-70,209
Closed -$817K
BAX icon
56
Baxter International
BAX
$14.2B
– –
-12,575
Closed -$1.01M
BIO icon
57
Bio-Rad Laboratories Class A
BIO
$9.42B
– –
-3,916
Closed -$2.02M
CNMD icon
58
CONMED
CNMD
$1.47B
– –
-81,205
Closed -$6.39M
CRBP icon
59
Corbus Pharmaceuticals
CRBP
$188M
– –
-2,996
Closed -$162K
DGX icon
60
Quest Diagnostics
DGX
$26.3B
– –
-29,041
Closed -$3.33M
DVA icon
61
DaVita
DVA
$11.7B
– –
-21,002
Closed -$1.8M
HAE icon
62
Haemonetics
HAE
$4B
– –
-41,607
Closed -$3.63M
IART icon
63
Integra LifeSciences
IART
$1.34B
– –
-281,608
Closed -$13.3M
IWM icon
64
PUT
iShares Russell 2000 ETF
IWM
$83B
– –
-80,500
Closed -$12.1M
MCK icon
65
McKesson
MCK
$101B
– –
-40,419
Closed -$6.02M
MGNX icon
66
MacroGenics
MGNX
$257M
– –
-97,374
Closed -$2.45M
PETS icon
67
PetMed Express
PETS
$42.3M
– –
-105,895
Closed -$3.35M
QNCX icon
68
Quince Therapeutics
QNCX
$29.5M
– –
-109
Closed -$1.09M
SAGE
69
DELISTED
Sage Therapeutics
SAGE
– –
-23,588
Closed -$1.44M
SPY icon
70
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$823B
– –
-91,300
Closed -$30.8M
XBI icon
71
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
– –
-52,000
Closed -$5.79M
ZBH icon
72
Zimmer Biomet
ZBH
$18.4B
– –
-55,861
Closed -$7.38M
RNTX
73
Rein Therapeutics
RNTX
$69.9M
– –
-13,172
Closed -$340K
PDCO
74
DELISTED
Patterson Companies, Inc.
PDCO
– –
-163,415
Closed -$3.94M
CALT
75
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
– –
-111,467
Closed -$2.67M
1 2
3
4

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Endurant Capital Management held 81 positions worth $277M, down 18% from $338M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Endurant Capital Management withdrew a net $112M in Q4 2020, closing 29 positions and reducing 18 holdings. Its most notable exit was Integra LifeSciences, an estimated $13.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 83% a quarter earlier.

Against the trend, Endurant Capital Management opened a new position in Becton Dickinson worth $17.3M.

  • Endurant Capital Management's largest Q4 2020 buy was Becton Dickinson: 70,996 shares worth $17.3M.
  • Endurant Capital Management added most to Oxford Immunotec Global PLC Ordinary Shares in Q4 2020, an estimated $6.82M increase.
  • Endurant Capital Management's biggest Q4 2020 reduction was Encompass Health, cutting an estimated $15M.
  • Endurant Capital Management fully exited Integra LifeSciences in Q4 2020, selling an estimated $13.3M.
  • Endurant Capital Management's ten largest holdings make up 47% of its $277M portfolio in Q4 2020.
  • Endurant Capital Management opened 21 new positions and closed 29 in Q4 2020.
  • Endurant Capital Management's portfolio value fell 18% quarter-over-quarter to $277M.

Based on Endurant Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.